Table 2 The sites of initial disease progression after response to gefitinib
Site | No. of patients | % |
|---|---|---|
Primary lesion | 8 | 29.6 |
Metastatic lesion | Â | Â |
   Intrapulmonary | 8 | 29.6 |
   Pleural effusion | 6 | 22.2 |
   Bone | 5 | 18.5 |
   CNS | 3 | 11.1 |
   Others | 0 | 0 |